Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

And GSK’s first-to-market Arexvy lived up to that expectation with $1.5 billion sales in its first year of commercialization. Related As RSV vaccine clash kicks off, GSK sues Pfizer for patent ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

GSK is one of the pharma industry's top vaccine producers, giving Affinivax' shot the marketing muscle it will need to challenge Pfizer's Prevnar 13 and Prevnar 20 products – targeting 13 and 20 ...

Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was up ...

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together. The Company is ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

Motilal Oswal Nifty Midcap 150 Index Fund (G) 7.50 26,048 0.38 Motilal Oswal Nifty Midcap 150 Index Fund-Dir (G) 7.50 26,048 0.38 UTI-Nifty Midcap 150 Quality 50 Index Fund (G) 6.07 21,061 2.53 ...